Greater price transparency needed for thyroid cancer treatment among US cancer centres

Nierengarten, Mary Beth

doi:10.1016/s1470-2045(21)00345-4

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…28 Hospital compliance with the price transparency mandate is low across multiple nononcologic procedures, from colonoscopies to tonsillectomies. 12,[29][30][31] Because assessments of compliance can refer both to the degree hospitals hew to the "letter of the law" or the extent to which their efforts enable patients and payers to easily find the information, assessing compliance is not straightforward. A recent research letter with focus on the former examined global compliance among all short-term acute care hospitals.…”

Section: Discussionmentioning

confidence: 99%

Association Between Cancer Center Accreditation and Compliance With Price Disclosure of Common Oncologic Surgical Procedures

Zhang

Cerullo

Esposito

et al. 2022

Journal of the National Comprehensive Cancer Network

View full text Add to dashboard Cite

Background: Cancer center accreditation status is predicated on several factors that measure high-value healthcare. However, price transparency, which is critical in healthcare decisions, is not a quality measure included for accreditation. We reported the rates of price disclosure of surgical procedures for 5 cancers (breast, lung, cutaneous melanoma, colon, and prostate) among hospitals ranked by the American College of Surgeon’s Commission on Cancer (ACS-CoC). Methods: We identified nonfederal, adult, and noncritical access ACS-CoC accredited hospitals and used the commercial Turquoise Health database to perform a cross-sectional analysis of hospital price disclosures for 5 common oncologic procedures (mastectomy, lobectomy, wide local excision for cutaneous melanoma, partial colectomy, prostatectomy). Publicly available financial reporting data were used to compile facility-specific features, including bed size, teaching status, Centers for Medicare & Medicaid wage index, and patient revenues. Modified Poisson regression evaluated the association between price disclosure and ACS-CoC accreditation after adjusting for hospital financial performance. Results: Of 1,075 total ACS-CoC accredited hospitals, 544 (50.6%) did not disclose prices for any of the surgical procedures and only 313 (29.1%) hospitals reported prices for all 5 procedures. Of the 5 oncologic procedures, prostatectomy and lobectomy had the lowest price disclosure rates. Disclosing and nondisclosing hospitals significantly differed in ACS-CoC accreditation, ownership type, and teaching status. Hospitals that disclosed prices were more likely to receive Medicaid disproportionate share hospital payments, have lower average charge to cost ratios (4.53 vs 5.15; P<.001), and have lower net hospital margins (−2.03 vs 0.44; P=.005). After adjustment, a 1-point increase in markup was associated with a 4.8% (95% CI, 2.2%–7.4%; P<.001) higher likelihood of nondisclosure. Conclusions: More than half of the hospitals did not disclose prices for any of the 5 most common oncologic procedures despite ACS-CoC accreditation. It remains difficult to obtain price transparency for common oncologic procedures even at centers of excellence, signaling a discordance between quality measures visible to patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Association Between Cancer Center Accreditation and Compliance With Price Disclosure of Common Oncologic Surgical Procedures

Zhang

Cerullo

Esposito

et al. 2022

Journal of the National Comprehensive Cancer Network

View full text Add to dashboard Cite

show abstract

“…TC is projected to surpass colorectal carcinoma as the fourth most common cancer overall by 2030 [ 1 ]. Owing to its low mortality rate and prolonged follow-up management, TC imposes a high healthcare burden and financial cost on the expanded survivor pool [ 2 , 3 , 4 ]. Papillary thyroid carcinomas (PTC) are the most common histological subtype, comprising 85% of all differentiated thyroid cancers.…”

Section: Introductionmentioning

confidence: 99%

A miRNA-Based Prognostic Model to Trace Thyroid Cancer Recurrence

Toraih

Fawzy

Niu

et al. 2022

Cancers

View full text Add to dashboard Cite

Papillary thyroid carcinomas (PTCs) account for most endocrine tumors; however, screening and diagnosing the recurrence of PTC remains a clinical challenge. Using microRNA sequencing (miR-seq) to explore miRNA expression profiles in PTC tissues and adjacent normal tissues, we aimed to determine which miRNAs may be associated with PTC recurrence and metastasis. Public databases such as TCGA and GEO were utilized for data sourcing and external validation, respectively, and miR-seq results were validated using quantitative real-time PCR (qRT-PCR). We found miR-145 to be significantly downregulated in tumor tissues and blood. Deregulation was significantly related to clinicopathological features of PTC patients including tumor size, lymph node metastasis, TNM stage, and recurrence. In silico data analysis showed that miR-145 can negatively regulate multiple genes in the TC signaling pathway and was associated with cell apoptosis, proliferation, stem cell differentiation, angiogenesis, and metastasis. Taken together, the current study suggests that miR-145 may be a biomarker for PTC recurrence. Further mechanistic studies are required to uncover its cellular roles in this regard.

show abstract

Rates of price disclosure associated with the surgical treatment of early-stage breast cancer one year after implementation of federal regulations

Shah,

Zhang,

Correa

et al. 2023

Breast Cancer Res Treat

View full text Add to dashboard Cite

Greater price transparency needed for thyroid cancer treatment among US cancer centres

Cited by 4 publications

References 0 publications

Association Between Cancer Center Accreditation and Compliance With Price Disclosure of Common Oncologic Surgical Procedures

Association Between Cancer Center Accreditation and Compliance With Price Disclosure of Common Oncologic Surgical Procedures

A miRNA-Based Prognostic Model to Trace Thyroid Cancer Recurrence

Rates of price disclosure associated with the surgical treatment of early-stage breast cancer one year after implementation of federal regulations

Contact Info

Product

Resources

About